Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. a human subject, and related methods and uses.

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the truncated L1 protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

An inactivated virus vaccine microneedle product includes a backing and an inactivated virus-containing microneedle array attached to a side of the backing, wherein the inactivated virus-containing microneedle array includes a plurality of microneedles, and each microneedle contains a matrix and an inactivated virus loaded in the matrix. The present invention adopts the inactivated virus vaccine microneedle product as well as a preparation method and an application thereof, and such microneedle product realizes efficient transdermal absorption of a vaccine by loading an inactivated virus in the microneedle product after being administered to the skin, and a long-acting stable release of a vaccine is achieved, which solves the problems of traditional vaccination, such as muscular pain and multiple injections.

The present invention provides an efficient process for culturing viruses in the presence of an endonuclease and for producing vaccines, typically from live attenuated viruses, under conditions to reduce the presence of host cell DNA and eliminate the need for a post-harvest DNA digestion step.

The present disclosure relates to a viral vector suitable for introducing a therapeutic agent, such as a peptide, protein or small RNA, into a host or otherwise treating a host. The vector may include an exogenous RNA segment with a hairpin-like structure or having two or more base-paired regions separated by one or more non-base-paired regions. The exogenous RNA segment may have a secondary structure, minimum free energy, average positional entropy or other attributes within specified ranges, or with values similar to one or more hairpin-like structures of a reference wild type virus. Optionally, the RNA vector may be derived from the reference wild type virus or a relative of the reference wild type virus. In some examples, the vector is capable of capable of systemic and phloem-limited movement and replication within a host plant. In some examples, the reference wild type virus is an umbravirus-like associated RNA.

The present invention provides an efficient process for culturing viruses in the presence of an endonuclease and for producing vaccines, typically from live attenuated viruses, under conditions to reduce the presence of host cell DNA and eliminate the need for a post-harvest DNA digestion step.

The present invention provides an efficient process for culturing viruses in the presence of an endonuclease and for producing vaccines, typically from live attenuated viruses, under conditions to reduce the presence of host cell DNA and eliminate the need for a post-harvest DNA digestion step.

Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. a human subject, and related methods and uses.

Methods of producing, propagating and multiplying viruses, methods of identifying the presence of a virus in a sample, specifically methods using Japanese eel cell cultures. Also provided are an isolated Japanese eel cell culture, optionally infected with a virus, vaccines comprising viruses grown according to the methods of the invention, and a kit for propagating viruses comprising the Japanese eel cell culture. The virus may be a fish virus such as nodavirus, Infectious Pancreatic Necrosis Virus (IPNV) and Salmon Pancreas Disease Virus (SPDV).

The culture medium of viruses for human vaccines have to consist of human cells from placenta and/or from umbilical cord of a fetus of the blood type 0 Rh (blood type 0 Rh negative) and of the mother of the blood type 0 Rh (both, fetus and mother, must be of the blood type 0 Rh).